← Back
Data updated: Jun 28, 2026
MARIUS
Pharma Pharmaceuticals
MARIUS is a pharmaceutical company with 1 FDA-approved products.
2022
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
MARIUS's Key Drugs
MARIUS's core commercial portfolio centers on KYZATREX — its most strategically important drugs approved in the last 15 years.
MARIUS's Recent FDA Approvals
New NDA/BLA approvals for MARIUS over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
MARIUS's Therapeutic Areas
Disease areas where MARIUS has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
MARIUS Pipeline Snapshot
Active clinical trials for MARIUS across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • KYZATREX leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2022-07-27
- Latest
- 2025-07-11
- Applications
- 1